03rd week of 2015 patent applcation highlights part 53 |
Patent application number | Title | Published |
20150018244 | MEANS AND METHODS FOR ASSESSING HYPERTHYROIDISM - The present invention pertains to the field of diagnostics for hyperthyroidism and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing hyperthyroidism. It also relates to a method for determining whether a compound is capable of inducing such hyperthyroidism in a subject and to a method of identifying a drug for treating hyperthyroidism. Furthermore, the present invention relates to a device and a kit for diagnosing hyperthyroidism. | 2015-01-15 |
20150018245 | LIPID ARRAYS ON FABRICATED DEVICES AND USES THEREOF - Systems and methods for arranging microdevices on an array substrate are described. Each microdevice contains a lipid bilayer region and a patterned magnetic material that has a predetermined preferential axis of magnetization. The microdevices are located at specific locations on the arraying substrates and a magnetic field is used to orient the microdevices to facilitate the study of lipids and lipid-associated moieties. The bilayer region can also contain a fluorescent reagent, which can be monitored during exposure to an excitation source. The fluorescent reagent can also be photobleached and monitored for fluorescence recovery. | 2015-01-15 |
20150018246 | POLYPEPTIDE MARKER FOR DIAGNOSING AND ASSESSING VASCULAR DISEASES - The invention relates to a method for diagnosing vascular diseases, comprising the step in which the presence, absence or amplitude of at least three polypeptide markers is determined in a urine sample, wherein the polypeptide markers are selected from the markers characterized in table 1 by values for the molecular masses and the migration time. | 2015-01-15 |
20150018247 | METHOD OF MANUFACTURING BIOMEDICAL MOLECULAR DETECTION PLATFORM AND THE DETECTION PLATFORM MANUFACTURED THEREFROM - The present invention provides a method of manufacturing biomedical molecular detection platform, comprising providing a plurality of reagent droplets on a first surface of a substrate; forming a plurality of hydrophilic regions and a water-repellant region on a second surface of a test paper, and the plurality of hydrophilic regions separated individually by the water-repellant region; and contacting the first surface of the substrate with the second surface of the test paper for transferring each reagent droplet on the substrate to each hydrophilic region of the test paper. The present invention also provides a biomedical molecular detection platform manufactured therefrom. The method of present invention can rapidly manufacture large quantity of biomedical molecular detection platforms, and the biomedical molecular detection platform can be used to any test that use pigmentation to determine results. | 2015-01-15 |
20150018248 | ARRAY PLATES FOR WASHING SAMPLES - Methods and systems for processing a first solution on a respective primary area of a device with a plurality of primary areas and a plurality of secondary areas are described. A method includes providing the device and dispensing a second solution to a respective secondary area of one or more secondary areas adjacent to the respective primary area, thereby mixing the first solution on the respective secondary area and the second solution on the respective primary area. The method also includes removing at least a portion of the mixed solution. | 2015-01-15 |
20150018249 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS - The present invention relates to a method for identifying a target nucleotide sequence. This method involves forming a ligation product on a target nucleotide sequence in a ligation detection reaction mixture, amplifying the ligation product to form an amplified ligation product in a polymerase chain reaction (PCR) mixture, detecting the amplified ligation product, and identifying the target nucleotide sequence. Such coupling of the ligase detection reaction and the polymerase chain reaction permits multiplex detection of nucleic acid sequence difference. | 2015-01-15 |
20150018250 | Symmetrically Branched Polymer Conjugates and Microarray Assays - Modified symmetrically branched polymers are combined with bioactive agents for a variety of purposes including drug delivery and conjugation to one member of a binding pair for use in an assay. | 2015-01-15 |
20150018251 | PROTEIN CHIPS, PREPARATION AND USE THEREOF - The present invention relates to the field of medicine, in particular of research and diagnosis. It relates more particularly to a novel tool for detecting antibodies in a biological sample originating from a mammal. This tool, which is in the form of a protein chip, can be used in screening for new targets of interest involved in the occurrence of an autoimmune disease, in particular of a disease affecting the nervous system of a mammal, and also in the diagnosis or the monitoring of the progression of such an autoimmune disease. The invention also relates to a method for producing such a tool and also to kits comprising it and enabling its use. | 2015-01-15 |
20150018252 | METHODS FOR PROVIDING AND DELIVERING AN ENVIRONMENTALLY SEALED CHIP - The invention provides methods relating methods for environmentally sealing, protecting, and providing analysis chips for processing and analysis. The analysis chips are bonded directly or indirectly to chip carriers which are held within the chambers of an environmental packaging strip. The chambers are sealed with a sealing film such that the chip carriers are extracted using a piercing tool and an extraction tool. | 2015-01-15 |
20150018253 | Methods and Compositions for Selective Labeling of Different Biotinylated Targets within Multicolor or Multilabel Assays - Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells. These multilabel assays are enabled through the use of biotin with desthiobiotin, orthogonal protecting schemes for biotin, or a combination of the approaches. | 2015-01-15 |
20150018254 | SLIDING ELEMENT FOR USE IN INTERNAL COMBUSTION ENGINE - A sliding element for use in an internal combustion engine may include a ferrous base having a peripheral sliding surface covered by a protective surface layer, the protective surface layer including at least one nitride applied via at least one of physical vapour deposition and a nitrided layer. The peripheral sliding surface may have a diamond like carbon (DLC) coating disposed thereon. The coating may include at least one of (a) one or more transition layers composed of WC1-x and (b) an adhesive layer of metallic chromium with a crystal structure. The coating may include an intermediate layer of metal DLC, the metal may be tungsten in a multilayer structure of a-C:H:W and a-C:H, and an outer layer of metal-free DLC. | 2015-01-15 |
20150018255 | SLIDING MEMBER AND SLIDING MATERIAL COMPOSITION - An object of the present invention is to provide a sliding member suitable to a soft mating member low in hardness. The present invention relates to a sliding member for sliding with a mating member having a ferrite phase at least on a surface thereof, the sliding member including a coating layer containing a binder resin, molybdenum disulfide, and hard substance particles. | 2015-01-15 |
20150018256 | LUBRICATING OIL COMPOSITION - A lubricating oil composition is provided having excellent torque capacity, shifting properties, and anti-wear properties for wet friction materials, which can maintain initial torque capacity and shifting properties for a long period of time, suitable for automatic and/or continuously variable transmissions. The lubricating oil composition contains a lubricating base oil and based on the total mass of the composition (A) 0.5 percent by mass or more of a fatty acid amide compound represented by formula (1); (B) 0.05 percent by mass or more of thiadiazole; and (C) 0.1 percent by mass of a phosphorus-containing additive, and contains sulfur in an amount of 0.2 percent by mass or more based on sulfur and phosphorus in an amount of 0.2 percent by mass or less based on phosphorus, the ratio of the sulfur basis percent by mass/the phosphorus basis percent by mass (S/P) being from 3.0 to 5.0: | 2015-01-15 |
20150018257 | SHOCK ABSORBER OIL COMPOSITION - A shock absorber oil composition of the invention includes a base oil: (A) at least one of phosphate, amine phosphate salt, phosphite and amine phosphite salt; (B) an amide compound; and (C) an N-substituted derivative of sarcosine. | 2015-01-15 |
20150018258 | MARINE ENGINE LUBRICATION - A detergent system that includes (i) an overbased C20-28 alkyl-substituted hydroxybenzoate Ca salt of TBN less than 250 and (ii) an overbased C14-18 alkyl-substituted hydroxybenzoate Ca salt of TBN less than 250, the wt % Ca ratio of (ii) to (i) being more than one, is used in a trunk piston marine lubricant to improve its asphaltene dispersancy when lubricating a medium-speed compression-ignited marine engine fuelled by a heavy fuel oil. | 2015-01-15 |
20150018259 | Lubricant Composition Comprising a Bi-Modal Side-Chain Distribution LOFI - A lubricant composition is disclosed. The lubricant composition is made up of (a) an API Group III base stock; (b) one or more semi-crystalline viscosity modifier; and (c) one or more LOFIs having a side-chain distribution which satisfies the following requirements: (1) the distribution contains side chains ranging from C | 2015-01-15 |
20150018260 | LUBRICANT COMPOSITION OF MATTER AND METHODS OF PREPARATION - Ester polyol esters are a unique class of lubricants that have adjustable molecular weights, viscosities, and pour points based on the character of their reaction materials and relative ratios. There is provided a method for preparing at least one ester polyol ester, the method comprising esterifying an ester polyol reaction mixture to produce ester polyol, the reaction mixture comprising an ozone acid mixture and at least one primary polyol, wherein the ozone acid mixture comprises at least one dicarboxylic acid and at least one monocarboxylic acid; and capping the ester polyol with at least one capping carboxylic acid to produce ester polyol ester. | 2015-01-15 |
20150018261 | POST CHEMICAL-MECHANICAL-POLISHING (POST-CMP) CLEANING COMPOSITION COMPRISING A SPECIFIC SULFUR-CONTAINING COMPOUND AND A SUGAR ALCOHOL OR A POLYCARBOXYLIC ACID - A post chemical-mechanical-polishing (post-CMP) cleaning composition comprising: (A) at least one compound comprising at least one thiol (—SH), thioether (—SR | 2015-01-15 |
20150018262 | Aluminum-Safe Surface Presoak Cleaner and Process - A presoak cleaning compound and cleaning process developed for compatible application to aluminum and common cooking surfaces including stainless steel, steel, ferrous, plastic or coated cooking surfaces including baking pans and sheet pans, or commonly used substrate materials for food preparation and cooking surfaces of food stuffs for the removal of food soils, baked on food soils, and soils resulting from the preparation and cooking of food stuffs without discoloration, tarnishing, or pitting of the surface. | 2015-01-15 |
20150018263 | LAUNDRY DETERGENT COMPOSITION - A laundry detergent composition comprising an agglomerate particle wherein the agglomerate particle comprises;
| 2015-01-15 |
20150018264 | LAUNDRY DETERGENT COMPOSITION - A laundry detergent composition comprising;
| 2015-01-15 |
20150018265 | NOVEL FORMULATION OF A WARE WASHING SOLID CONTROLLING HARDNESS - A water hardness controlling agent includes a polyacrylic acid or salt thereof having a molecular weight of between about 1,000 and about 50,000 g/mol, an acrylic-maleic acid copolymer or salt thereof having a molecular weight of between about 1,000 and about 100,000 g/mol and a phosphonocarboxylic acid or salt thereof. A ratio of acrylic-maleic acid copolymer or salt thereof to polyacrylic acid or salt thereof to phosphonocarboxylic acid or salt thereof in parts per million is about 1-30:10-80:6-20. | 2015-01-15 |
20150018266 | STEARYL AND LAURYL DIMONIUMHYDROXY ALKYL POLYGLUCOSIDES FOR ENHANCED FOOD SOIL REMOVAL - A cleaning composition including a primarily C | 2015-01-15 |
20150018267 | Endomucin As An Anti-Inflammatory Agent - The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory Agent | 2015-01-15 |
20150018268 | MULTIVALENT SYNTHETIC COMPOUNDS AS ANTIBIOTIC TREATMENT - The present invention relates to the use of a multivalent synthetic compound, which is significantly more resistant to at least one protease than a standard peptide bond, for preparing a medication, and methods of use for the treatment of diseases, e.g., due to bacterial and/or microbial growth. | 2015-01-15 |
20150018269 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND USE THEREOF - The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases. | 2015-01-15 |
20150018270 | ISOLATION, IDENTIFICATION, AND USES OF ANTIFUNGAL COMPOUNDS - In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: | 2015-01-15 |
20150018271 | HSP60 DERIVED PEPTIDES AND PEPTIDE ANALOGS FOR SUPPRESSION AND TREATMENT OF NON-AUTOIMMUNE DIABETES - The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60), and for suppression, prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277™, a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression, prevention or treatment of T2D. | 2015-01-15 |
20150018272 | COMPOSITIONS AND METHODS OF USING PROISLET PEPTIDES AND ANALOGS THEREOF - Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof. | 2015-01-15 |
20150018273 | NOVEL COMPOSITIONS AND USES THEREOF - The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an RGD domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal. | 2015-01-15 |
20150018274 | ERYTHROPOIETIN-DERIVED SHORT PEPTIDE AND ITS MIMICS AS IMMUNO/INFLAMMATORY MODULATORS - The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof. | 2015-01-15 |
20150018275 | METHODS OF IMPROVING BEHAVIORAL THERAPIES - This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy. | 2015-01-15 |
20150018276 | METHOD OF TREATMENT OF CANCER USING GUANOSINE 3', 5' CYCLIC MONOPHOSPHATE (CYCLIC GMP) - A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas. | 2015-01-15 |
20150018277 | Combination of a Leucine Source and an Omega-3 Unsaturated Fatty Acid Source for Use in the Treatment of Hypercalcaemia - The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis. | 2015-01-15 |
20150018278 | PHOSPHORYLATION ON THE THR-248 AND/OR THR-250 RESIDUES OF TRANSCRIPTION FACTOR E2F4 AS A THERAPEUTIC TARGET IN PATHOLOGICAL PROCESSES ASSOCIATED WITH SOMATIC POLYPLOIDY - The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4. | 2015-01-15 |
20150018279 | COMPOSITIONS AND METHODS FOR DELIVERY OF KINASE INHIBITING PEPTIDES - The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states. | 2015-01-15 |
20150018280 | FOAMED BIOCOMPATIBLE MATERIALS FOR TISSUE REPAIR - A foamed biocompatible material for use in tissue repair and a kit for producing same. The kit includes a container having a valve and an inlet, and a tissue-repair composition containing a biocompatible material and a liquid carrier, in which the composition is placed in the inlet of the container and the inside of container has a pressure lower than that of the outside so that, upon opening the valve, the composition is forced into the container by the pressure difference to form a foam inside the container. Also disclosed is a method of preparing a foamed biocompatible material for tissue repair. | 2015-01-15 |
20150018281 | Compositions and Methods for Uncoupling TrkB Receptor from PLC gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase Cγ1 (PLCγ1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLCγ1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures. | 2015-01-15 |
20150018282 | PREPARATION FOR IMPROVING MEMORY AND LEARNING AND USE THEREOF - The invention relates to a preparation for improving memory and learning comprising enzymatic protein hydrolyzate of animal nervous tissue, preferably the tissue of spinal cord of animals for slaughter, while the preferred protein being a myelin protein. The invention also relates to composition for use in treatment of memory disorders, in particular age associated memory disorders and learning impairment. Also disclosed is the method for improving memory and learning. | 2015-01-15 |
20150018283 | METHODS FOR TREATING PAIN - The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS. | 2015-01-15 |
20150018284 | FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES - This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. | 2015-01-15 |
20150018285 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS - The present invention provides an antagonist of a Bcl-2 pro survival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders. | 2015-01-15 |
20150018286 | ANTITUMOR PEPTIDE AND USE THEREOF - This invention provides an antitumor peptide and an antitumor composition that includes the peptide for suppressing proliferation of at least one species of tumor cells. The antitumor composition provided by this invention includes an antitumor peptide capable of inducing formation of multipolar spindles in at least one species of tumor cells, and at least one species of pharmaceutically acceptable carrier, wherein the antitumor peptide is a synthetic peptide having an amino acid sequence selected from SEQ ID NOs: 1 to 22 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the selected amino acid sequence. | 2015-01-15 |
20150018287 | EYE DROPS - An eye drop containing (i) a peptide having an amino acid sequence which is represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmaceutically acceptable salt thereof and (ii) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH | 2015-01-15 |
20150018288 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof. | 2015-01-15 |
20150018289 | NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity. | 2015-01-15 |
20150018290 | INDUCERS OF HEMATOPOIESIS AND FETAL GLOBIN PRODUCTION FOR TREATMENT OF CYTOPENIAS AND HEMOGLOBIN DISORDERS - The present invention generally relates to compositions containing chemical compounds and compositions and pharmaceutical formulations of the compounds which increase the expression of total hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other blood cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia, and other blood cell deficiencies and blood disorders. The invention also relates to methods for administering these compositions to subjects and for use as medical aids for the treatment and prevention of blood and other disorders. | 2015-01-15 |
20150018291 | The Utility of Nematode Small Molecules - The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside. | 2015-01-15 |
20150018292 | BIOACTIVE ALKALOID COMPOSITIONS AND THEIR MEDICAL USES - The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from | 2015-01-15 |
20150018293 | ANIMAL TREATMENTS - Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal. | 2015-01-15 |
20150018294 | MODULATORS OF TOUSLED KINASE IN CELLULAR PROCESSES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides for methods and pharmaceutical agents to modulate the activity of Tousled-like kinase (TLK). The invention also provides for methods and pharmaceutical agents to inhibit the activity of Tousled-like kinase to provide increased sensitivity to irradiation (IR) and chemotherapeutic agents. The invention also provides for methods and pharmaceutical agents to increase the activity of Tousled-like kinase to provide increased protection against DNA damaging agents including to irradiation (IR) and chemotherapeutic agents. | 2015-01-15 |
20150018295 | METHOD FOR THE PREPARATION OF TRIGLYCERIDES OF MEDIUM-CHAIN LENGTH FATTY ACIDS - A method is disclosed for the preparation of glycerol esters (triglycerides) of medium-chain length monocarboxylic fatty acids which consists of the reaction of the precursor free fatty acid and glycerol in the presence of a catalyst under partial vacuum. The process preferably uses a metal catalyst such as an oxide or a chloride of tungsten, molybdenum, calcium, zinc, chromium or magnesium. The method of the invention allows the preparation in high yield and high purity (>99.5%) of the final triglyceride. The present method allows the formation of triglycerides without solvent. Are also contemplated, the triglyceride obtained by the method, and the pharmaceutical composition containing the triglyceride as an excipient or as an active ingredient. | 2015-01-15 |
20150018296 | THERAPEUTIC METHODS AND COMPOSITIONS UTILIZING CYCLOHEXENONE COMPOUNDS - The present invention is directed to therapeutic methods and compositions involving cyclohexenone compounds where said compounds inhibit farnesyltransferase or Ras. The therapeutic methods (e.g. for treating cancers) comprise contacting a tumor with a cyclohexenone compound and an anticancer agent. | 2015-01-15 |
20150018297 | COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES INCLUDING COMPOUND DOWNREGULATING EXPRESSION OF BACE1 PROTEINS - The present disclosure relates to a pharmaceutical composition, a health functional food composition, and a method for preventing or treating a brain disease or diabetes. The pharmaceutical composition, health functional food composition, and method includes at least one active ingredient that is chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfuram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, or topotecan. | 2015-01-15 |
20150018298 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE - Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): | 2015-01-15 |
20150018299 | TREATMENT OF LIVER CONDITIONS - The present disclosure concerns the A | 2015-01-15 |
20150018300 | COMPOUNDS - Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. | 2015-01-15 |
20150018301 | LRRK-2-Mediated Neuronal Toxicity - Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease. | 2015-01-15 |
20150018302 | COMPOSITIONS COMPRISING NDGA DERIVATIVES AND SORAFENIB AND THEIR USE IN TREATMENT OF CANCER - The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided. | 2015-01-15 |
20150018303 | COMPOSITIONS OF HYALURONAN WITH HIGH ELASTICITY AND USES THEREOF - The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity. | 2015-01-15 |
20150018304 | DIET PRODUCT COMPRISING ALGINATE - The present invention relates to a diet product comprising an alginate in an aqueous dissolved or swelled form at a pH value causing the alginate not to gel until after it is consumed and comes into contact gastric acid. | 2015-01-15 |
20150018305 | SIRTUIN INDUCER, TISSUE REPAIRING AGENT, HEPATOCYTE GROWTH FACTOR INDUCER, TISSUE HOMEOSTASIS MAINTENANCE AGENT, AND TLR4 AGONIST, HAVING HYALURONIC ACID FRAGMENT AS ACTIVE INGREDIENT - Provided are a sirtuin inducer, a tissue repairing agent, a hepatocyte growth factor inducer, a tissue homeostasis maintenance agent, and a TLR4 agonist, which utilize a hyaluronic acid fragment as an active ingredient. | 2015-01-15 |
20150018306 | CHITOSAN BASED HIGH PERFORMANCE FILTER WITH SELF-REGENERATING ABILITY - A self-regenerating chitosan based filter medium for disinfecting and purifying organic pollutants and other pollutants in a gas or liquid is disclosed herein. Porosity and surface charge of said filter medium is manipulative/tunable by varying one or more of the following parameter(s): concentration of chitosan, crosslinking density, amount of copolymers and additives, freezing temperature, freezing profile, and/or types of crosslinker used. The present filter medium is capable of self-regenerating under exposure to ultra-violet light for sufficient time and removing over 90% of the pollutants from each influent flowing through the filter medium. | 2015-01-15 |
20150018307 | DEODORANT COMPOSITIONS - A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent. | 2015-01-15 |
20150018308 | Preparation of Triple Responsive Nanogel System and its Application - A thermal triple-responsive polymer, along with methods of its formation and use, is generally provided. The thermal triple-responsive polymer can comprise poly[(2-(pyridin-2-yldisulfanyl)-co-[poly(ethylene glycol)]-co-[N-isopropyl methacrylamide], which contains both disulfide bonds and ester bonds that are labile to high redox potential and acidic pH, respectively, and temperature sensitive segments. The thermal triple-responsive polymer can be modified with 4-methoxybenzoic acid to endow tumor targeting effect. Nanoparticles and nanogels that include such a thermal triple-responsive polymer are also provided, along with their methods of formation and use. | 2015-01-15 |
20150018309 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 - In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M | 2015-01-15 |
20150018310 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 2015-01-15 |
20150018311 | THERAPEUTIC BORON-CONTAINING COMPOUNDS - The present invention relates to compounds of Formula (I) wherein R | 2015-01-15 |
20150018312 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 2015-01-15 |
20150018313 | NOVEL 5-SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS - The present invention relates to compounds of general formula (I) | 2015-01-15 |
20150018314 | NOVEL BENZIMIDAZOLIUM COMPOUNDS - The present invention relates to compounds of general formula (I) | 2015-01-15 |
20150018315 | NOVEL TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS - The present invention relates to compounds of general formula (I) | 2015-01-15 |
20150018316 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development - The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function. | 2015-01-15 |
20150018317 | BIOCIDAL COMPOSITION - A biocidal composition comprising tributyl tetradecyl phosphonium chloride and tetrakis(hydroxymethyl)phosphonium sulfate at a weight ratio of 2:1 to 1:10, and its use for the control of microorganisms in aqueous and water-containing systems. | 2015-01-15 |
20150018318 | Glycosidase inhibitors - Novel compounds of formula (I) | 2015-01-15 |
20150018319 | TREATMENT OF SKIN DISEASE - The present invention is drawn to compositions, systems, and methods of treating skin disease. The composition includes a peroxygen, a transition metal or alloy thereof, and optionally, an alcohol and/or a drug. The composition can be packaged as part of a two-part system, and in one example, the drug is acetylsalicylic acid. | 2015-01-15 |
20150018320 | Hormone Containing Emulsion Comprising Krill Phospholipids - The invention relates to hormone containing oil-in-water emulsion for parenteral administration comprising progestogen and/or estrogen; a phospholipid comprising one or two omega-3 fatty acid moieties; and an oil as well as a pharmaceutical composition comprising or consisting of said oil-in-water emulsion. The pharmaceutical is especially for use in the treatment or prophylaxis of neurological damage after strokes and/or trauma and/or for use in the treatment or prophylaxis of neurological damage after concussion and/or traumatic injury to the central nervous system. | 2015-01-15 |
20150018321 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 2015-01-15 |
20150018322 | PRO-DRUG FORMING COMPOUNDS - Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO | 2015-01-15 |
20150018323 | 3B-HYDROXYSTEROID DEHYDROGENASE IN STEROID-DEPENDENT DISEASE - Methods and kits for characterizing a subject having a steroid-dependent disease such as prostate cancer are described. A method of treating a steroid-dependent disease in a subject by obtaining a biological sample from the subject, determining if the HSD3B1(1245C) gene or 3βHSD1(367T) protein is expressed in the biological sample, and providing treatment other than or in addition to steroid ablation to the subject if the HSD3B1(1245C) gene or 3βHSD1(367T) protein is expressed is also described. | 2015-01-15 |
20150018324 | TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier. | 2015-01-15 |
20150018325 | METHOD FOR LATE POST COITAL CONTRACEPTION USING ULIPRISTAL ACETATE - The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotected intercourse. | 2015-01-15 |
20150018326 | COMPOSITIONS AND METHODS FOR INHIBITING NOROVIRUS INFECTION - A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection. | 2015-01-15 |
20150018327 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS - Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders. | 2015-01-15 |
20150018328 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. | 2015-01-15 |
20150018329 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES - The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase. | 2015-01-15 |
20150018330 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS - The invention provides novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative | 2015-01-15 |
20150018331 | ANTIBACTERIAL AGENTS - Antibacterial compounds of formula (I) are provided: | 2015-01-15 |
20150018332 | Nuclear Transport Modulators and Uses Thereof - The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. | 2015-01-15 |
20150018333 | INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 2015-01-15 |
20150018334 | INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A | 2015-01-15 |
20150018335 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME - This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition. | 2015-01-15 |
20150018336 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2015-01-15 |
20150018337 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2015-01-15 |
20150018338 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to novel heterocyclic compounds of the formula | 2015-01-15 |
20150018339 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS - Compounds having the general formula II, III, or IV | 2015-01-15 |
20150018340 | PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS - The present invention relates to compounds having a pipecolate diketoamide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said pipecolate diketoamide compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions. | 2015-01-15 |
20150018341 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS - The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions. | 2015-01-15 |
20150018342 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals - The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example. | 2015-01-15 |
20150018343 | Tetraaza-cyclopenta[a]indenyl and their use as Positive Allosteric Modulators - The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator. | 2015-01-15 |